Compare Stocks: RANI, CABA, PRTA, and PBYI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$2.49 -4.2%	$2.92	$1.91 ▼ $4.23	$439.97M	3.27	5.25 million shs	6.14 million shs
PBYI Puma Biotechnology	$9.39 +1.5%	$8.71	$4.30 ▼ $9.73	$477.49M	1.24	288,825 shs	188,827 shs
PRTA Prothena	$8.24 -1.1%	$8.95	$7.73 ▼ $11.80	$436.10M	-0.33	321,791 shs	398,335 shs
RANI Rani Therapeutics	$0.76 -8.0%	$0.80	$0.45 ▼ $3.87	$114.51M	0.69	525,863 shs	1.42 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	-10.65%	-20.49%	-5.45%	-8.45%	+36.13%
PBYI Puma Biotechnology	+1.20%	-1.49%	+4.76%	+27.94%	+99.35%
PRTA Prothena	-5.98%	-12.68%	-5.98%	-1.88%	+2.08%
RANI Rani Therapeutics	-1.71%	-5.85%	+3.19%	+7.36%	+68.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$2.49 -4.2%	$2.92	$1.91 ▼ $4.23	$439.97M	3.27	5.25 million shs	6.14 million shs
PBYI Puma Biotechnology	$9.39 +1.5%	$8.71	$4.30 ▼ $9.73	$477.49M	1.24	288,825 shs	188,827 shs
PRTA Prothena	$8.24 -1.1%	$8.95	$7.73 ▼ $11.80	$436.10M	-0.33	321,791 shs	398,335 shs
RANI Rani Therapeutics	$0.76 -8.0%	$0.80	$0.45 ▼ $3.87	$114.51M	0.69	525,863 shs	1.42 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	-10.65%	-20.49%	-5.45%	-8.45%	+36.13%
PBYI Puma Biotechnology	+1.20%	-1.49%	+4.76%	+27.94%	+99.35%
PRTA Prothena	-5.98%	-12.68%	-5.98%	-1.88%	+2.08%
RANI Rani Therapeutics	-1.71%	-5.85%	+3.19%	+7.36%	+68.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	2.75	Moderate Buy	$15.33	517.04% Upside
PBYI Puma Biotechnology	2.00	Hold	$6.00	-35.41% Downside
PRTA Prothena	2.75	Moderate Buy	$24.57	199.29% Upside
RANI Rani Therapeutics	2.83	Moderate Buy	$8.75	977.59% Upside

Current Analyst Ratings Breakdown

Latest RANI, CABA, PRTA, and PBYI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
8/26/2026	RANI Rani Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	CABA Cabaletta Bio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/21/2026	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	RANI Rani Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/14/2026	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$4.00 ➝ $3.00
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/7/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	PBYI Puma Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$5.00 ➝ $6.00

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.16 per share	N/A
PBYI Puma Biotechnology	$228.40M	2.10	$0.85 per share	10.96	$2.59 per share	3.59
PRTA Prothena	$54.53M	7.88	N/A	N/A	$5.21 per share	1.58
RANI Rani Therapeutics	$1.63M	69.44	N/A	N/A	$0.34 per share	2.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$167.86M	-$1.57	N/A	N/A	N/A	N/A	-128.27%	-95.47%	11/9/2026 (Estimated)
PBYI Puma Biotechnology	$31.11M	$0.52	17.87	66.36	N/A	11.50%	20.76%	13.22%	11/5/2026 (Estimated)
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	3.12	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)
RANI Rani Therapeutics	-$29.67M	-$0.27	N/A	N/A	N/A	N/A	-104.60%	-65.17%	11/5/2026 (Estimated)

Latest RANI, CABA, PRTA, and PBYI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CABA Cabaletta Bio	-$0.3729	-$0.34	+$0.0329	-$0.34	$1.67 million	N/A
8/13/2026	Q2 2026	RANI Rani Therapeutics	-$0.05	-$0.04	+$0.01	-$0.04	$0.93 million	$1.71 million
8/6/2026	Q2 2026	PBYI Puma Biotechnology	$0.04	$0.19	+$0.15	$0.16	$53.00 million	$56.50 million
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	5.79	5.79
PBYI Puma Biotechnology	N/A	2.91	2.64
PRTA Prothena	N/A	25.05	25.05
RANI Rani Therapeutics	N/A	5.31	5.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
PBYI Puma Biotechnology	61.29%
PRTA Prothena	97.08%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	6.44%
PBYI Puma Biotechnology	22.20%
PRTA Prothena	10.40%
RANI Rani Therapeutics	26.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	158	169.54 million	158.63 million	Optionable
PBYI Puma Biotechnology	179	51.62 million	40.16 million	Optionable
PRTA Prothena	67	52.35 million	46.91 million	Optionable
RANI Rani Therapeutics	69	139.40 million	102.14 million	Optionable

RANI, CABA, PRTA, and PBYI Headlines

Recent News About These Companies

Rani Therapeutics to Participate in Upcoming September Conferences

September 8, 2026 | globenewswire.com

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 29, 2026 | marketbeat.com

Chardan Capital Upgrades Rani Therapeutics (NASDAQ:RANI) to Strong-Buy

August 28, 2026 | marketbeat.com

AWM Investment Company Inc. Purchases Shares of 7,500,000 Rani Therapeutics Holdings, Inc. $RANI

August 26, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Sanofi (OtherSNYNF)

August 25, 2026 | theglobeandmail.com

HC Wainwright Issues Pessimistic Forecast for RANI Earnings

August 25, 2026 | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Rani Therapeutics (NASDAQ:RANI)

August 21, 2026 | marketbeat.com

Canaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

August 20, 2026 | theglobeandmail.com

Chardan Capital Initiates Coverage on Rani Therapeutics (NASDAQ:RANI)

August 18, 2026 | marketbeat.com

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

August 13, 2026 | globenewswire.com

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 10, 2026 | markets.businessinsider.com

Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair

August 4, 2026 | quiverquant.comQ

Rani Therapeutics (NASDAQ:RANI) CEO Talat Imran Sells 8,014 Shares of Stock

July 29, 2026 | insidertrades.com

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | globenewswire.com

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

July 15, 2026 | globenewswire.com

Rani Therapeutics Holdings (RANI) Declines 7.95%, Testing Key Support at $0.60 - Strangle Setup

July 14, 2026 | donanimhaber.comD

Rani Therapeutics Holdings Inc - Ordinary Shares Class A

July 13, 2026 | money.usnews.com

Rani Therapeutics enters R&D collaboration with PegBio to expand obesity pipeline across multiple novel candidates

July 13, 2026 | pharmabiz.comP

Why Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration?

July 10, 2026 | kalkinemedia.comK

China's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani Therapeutics

July 10, 2026 | yicaiglobal.comY

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

July 9, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RANI, CABA, PRTA, and PBYI Company Descriptions

Cabaletta Bio NASDAQ:CABA

$2.49 -0.11 (-4.23%)

Closing price 04:00 PM Eastern

Extended Trading

$2.57 +0.08 (+3.05%)

As of 07:59 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Puma Biotechnology NASDAQ:PBYI

$9.39 +0.14 (+1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$9.39 0.00 (0.00%)

As of 07:30 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Prothena NASDAQ:PRTA

$8.24 -0.09 (-1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$8.24 0.00 (0.00%)

As of 07:30 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Rani Therapeutics NASDAQ:RANI

$0.76 -0.07 (-7.97%)

Closing price 04:00 PM Eastern

Extended Trading

$0.77 +0.01 (+1.72%)

As of 07:45 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RANI, CABA, PRTA, and PBYI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RANI, CABA, PRTA, and PBYI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RANI, CABA, PRTA, and PBYI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RANI, CABA, PRTA, and PBYI Company Descriptions

Cabaletta Bio NASDAQ:CABA

Puma Biotechnology NASDAQ:PBYI

Prothena NASDAQ:PRTA

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RANI, CABA, PRTA, and PBYI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RANI, CABA, PRTA, and PBYI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RANI, CABA, PRTA, and PBYI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RANI, CABA, PRTA, and PBYI Company Descriptions

Cabaletta Bio NASDAQ:CABA

Puma Biotechnology NASDAQ:PBYI

Prothena NASDAQ:PRTA

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools